Open Accessibility Menu
Hide

Breast Clinical Trials

Study Name: ASCENT-05

  • Cancer Stage: I-III
  • Key Inclusion: TNBC; Residual Disease
  • Description: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/​AFT-65 OptimICE-RD/​NSABP B-63).
  • Study Number: GS-US-595-6184
  • NCT#: NCT05633654

Study Name: OFSET

  • Cancer Stage: I-II
  • Key Inclusion: Oncotype 16-26
  • Description: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/​HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
  • Study Number: NRG-BR009
  • NCT#: NCT05879926

Study Name: CC011

  • Cancer Stage: I-III
  • Key Inclusion: Survivor
  • Description: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors.
  • Study Number: NRG-CC011
  • NCT#: NCT05896189

Study Name: OptimICE-PCR

  • Cancer Stage: I-II
  • Key Inclusion: CR TNBC Adjuvant
  • Description: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab.
  • Study Number: A012103
  • NCT#: NCT05812807

Study Name: Scarlet

  • Cancer Stage: N/A
  • Key Inclusion: N/A
  • Description: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
  • Study Number: S2212
  • NCT#: NCT05929768

Study Name: EAQ202

  • Cancer Stage: N/A
  • Key Inclusion: N/A
  • Description: Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
  • Study Number: EAQ202
  • NCT#: NCT05108298

Study Name: S2206

  • Cancer Stage: II-III
  • Key Inclusion: MammaPrint Index Score, HER2+
  • Description: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  • Study Number: S2206
  • NCT#: NCT06058377

Study Name: Short-STOP

  • Cancer Stage: II-III
  • Key Inclusion: HER2+
  • Description: ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  • Study Number: A012303
  • NCT#: NCT06876714

For more information, call 240-566-4100

All Locations